GC Genome Corp
KOSDAQ:340450
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GC Genome Corp
KOSDAQ:340450
|
KR |
|
Circle Internet Group Inc
F:ET9
|
US |
|
K
|
Kali Metals Ltd
ASX:KM1
|
AU |
|
Sera Prognostics Inc
NASDAQ:SERA
|
US |
|
Vaarad Ventures Ltd
BSE:532320
|
IN |
|
Yunfeng Financial Group Ltd
F:MNA1
|
HK |
|
Elcora Advanced Materials Corp
F:ELM0
|
CA |
|
Ocumetics Technology Corp
XTSX:OTC
|
CA |
|
Veejay Lakshmi Engineering Works Ltd
BSE:522267
|
IN |
|
N
|
NV Gold Corp
OTC:NVGLF
|
CA |
Bankruptcy Probability
GC Genome Corp's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Financial Position
| Jun 30, 2026 | 42.1B |
| Mar 31, 2026 | 42.7B |
| Dec 31, 2025 | 40.1B |
| Sep 30, 2025 | 41.5B |
| Jun 30, 2026 | 17.9B |
| Mar 31, 2026 | 17.7B |
| Dec 31, 2025 | 17.4B |
| Sep 30, 2025 | 14.5B |
| Jun 30, 2026 | 2.9B |
| Mar 31, 2026 | 3.1B |
| Dec 31, 2025 | 3.2B |
| Sep 30, 2025 | 3.4B |
Solvency Ratios
Solvency Ratios Comparison
GC Genome Corp Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KR |
G
|
GC Genome Corp
KOSDAQ:340450
|
214B KRW |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
504.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
237.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
193.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
132.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
79.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.4B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
58B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
48.9B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
40.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
GC Genome Corp's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, GC Genome Corp has total debt of 2.9B KRW. This includes both short-term (0 KRW) and long-term (2.9B KRW) debt.
You can find a full breakdown on its Balance Sheet.